Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.
about
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseProtein restriction for children with chronic kidney diseaseAngiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseGuidelines for the management of chronic kidney diseaseA novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on bloodDoes the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review.Aldosterone as a determinant of cardiovascular and renal dysfunctionIdentifying and slowing progressive chronic renal failureIndomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysisInhibition of G0/G1 Switch 2 Ameliorates Renal Inflammation in Chronic Kidney DiseaseProtection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of HypertensionMechanisms underlying renoprotection during renin-angiotensin system blockade.The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.Automating and estimating glomerular filtration rate for dosing medications and staging chronic kidney disease.Stem cell-based cell therapy for glomerulonephritisAngiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.World kidney day 2011: protect your kidneys, save your heart.Blood pressure control and progression of CKD in children.Hypertensive nephropathy: prevention and treatment recommendations.Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action.Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies.Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Remission of renal disease: recounting the challenge, acquiring the goalNephrology: 4. Strategies for the care of adults with chronic kidney disease.Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study resultsSlowing nephropathy progression: focus on proteinuria reduction.ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease.Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney diseaseEvidence-based guide to slowing the progression of early renal insufficiency.World Kidney Day 2011 - Protect your kidneys, save your heart.Sodium intake, ACE inhibition, and progression to ESRD.Antifibrotic effect of tamoxifen in a model of progressive renal disease.Early chronic kidney disease: diagnosis, management and models of care
P2860
Q24235834-AC19B378-3898-4ED3-8EB3-D51534B5E4FEQ24243491-0FABED9C-FA8A-496E-ABCF-C080CE85E5F2Q24244197-37B46D68-42BE-4AC6-91CC-C040085670F6Q24657844-6BBD3350-B743-4274-874F-64B4A5D5394CQ24806038-76EC5459-02AE-41BC-AED7-F8669EB39410Q24816744-03E5F91B-3367-459A-B0F9-23B1EF93E819Q28344356-AD40A2C5-4259-4ED8-A8A9-67F36D34E305Q28344781-C9735C81-667D-458F-83DD-38181CC0451BQ28729196-41954F75-59F3-4672-A62A-440202F697A2Q28818297-3674BFBC-7ACF-4B62-B679-E347E1780A34Q30249156-F07FADC8-F65E-4432-95FC-77176F1B7C08Q30499043-76C7590E-2FC8-4BDC-875E-807A00104B02Q30499045-225BFECA-CE08-4F65-9DB5-82F1BCBCBA1DQ32032668-B79F7412-92E6-4697-A16E-69E9D5B3C1A0Q33325660-C720A5F8-3194-4724-B6B0-B0D590E086E1Q33583503-83A868BE-250D-4469-93A3-30546C816A6FQ33805069-DFA9B862-2CB8-441E-8DBD-C9C8FE8E9898Q33836604-831D66C3-755D-4804-8E29-D487F7A5D341Q33871733-BAEF6871-A68A-4DEE-999E-7D854A550EDFQ33886069-BE5D44F6-9843-45EE-8DD6-55D641678C41Q34131899-9502D90C-EED8-4798-9A87-4AA36E46F472Q34331403-DE74D49B-8472-4515-9CE6-7D93E65C64F0Q34391213-F3B176BF-994E-403F-96C7-46B06A1DA178Q34405404-760A4A79-CB73-41B3-A3C1-C2A2130C43CEQ34448783-1CBEC24C-85F5-4B53-A031-028D8193E4EBQ34658876-56E448AA-D464-4CF6-8EA1-CED0AA692668Q34736194-CDCB6D1F-6635-42D4-91A9-4B1BA83D526EQ34774598-51564766-C7CE-4593-B9B3-DA00FF673A3BQ35028657-12D8DB3E-BA74-4603-B572-0E87AC215C2CQ35031111-493D2308-C325-4134-838D-5E07A9051963Q35115546-8BCB5EBE-40DF-4BF3-BF55-19ECDE3A0C1CQ35153298-4674079C-EF51-40AD-B3D9-23BD40FC8E43Q35154543-1D9CEC77-3068-43F2-BBA6-D02E14C1AAE4Q35164724-ABFB5472-54E7-46C4-A368-367A54395A4EQ35626544-DC4C61A0-4989-4FE2-B528-3152E6EF100BQ35641499-C0965EE5-9165-44EC-8E0D-A13E8AC63128Q35673984-74FEDA70-AE04-4D60-8D51-89098B1589BDQ35720736-77C8F132-1E2A-4DA6-958C-89D40D16142CQ35720759-D19FB07B-F4B0-41B0-A7DF-C4BE26143957Q35938045-095FC5FD-EBA5-44C2-9E79-789F8478AD68
P2860
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Renal function and requirement ...... ipril Efficacy in Nephropathy.
@ast
Renal function and requirement ...... ipril Efficacy in Nephropathy.
@en
Renal function and requirement ...... i Epidemiologici in Nefrologia
@nl
type
label
Renal function and requirement ...... ipril Efficacy in Nephropathy.
@ast
Renal function and requirement ...... ipril Efficacy in Nephropathy.
@en
Renal function and requirement ...... i Epidemiologici in Nefrologia
@nl
prefLabel
Renal function and requirement ...... ipril Efficacy in Nephropathy.
@ast
Renal function and requirement ...... ipril Efficacy in Nephropathy.
@en
Renal function and requirement ...... i Epidemiologici in Nefrologia
@nl
P2093
P50
P1433
P1476
Renal function and requirement ...... ipril Efficacy in Nephropathy.
@en
P2093
P304
P356
10.1016/S0140-6736(98)04433-X
P407
P577
1998-10-01T00:00:00Z